| Molly Ce Cowdrey, MD | |
|
176 S River Rd, Bedford, NH 03110-7061 | |
| (802) 909-2053 | |
| Not Available |
| Full Name | Molly Ce Cowdrey |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 10 Years |
| Location | 176 S River Rd, Bedford, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730599473 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 275622 (Massachusetts) | Secondary |
| 207N00000X | Dermatology | 18468 (New Hampshire) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optima Dermatology Llc | 3971561648 | 45 |
News Archive
A team of scientists from Spain has recently evaluated the immune responses induced by mRNA-based Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine in healthcare workers with or without a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Today, the Mental Health Now, or mhNOW, initiative will launch at the inaugural Financing and Innovation in Global Health (FIGH) conference. Led by mental health experts Chris Underhill, founder and president of BasicNeeds, and Moitreyee Sinha, head of health at the Global Development Incubator (GDI), mhNOW is a global, collective action including social entrepreneurs, organizations and companies that are working together to innovate and identify mental health solutions on a global scale, and systemically implement in communities at a local level.
A new vision screening device, already shown to give an early warning of eye disease, could give doctors and patients a head start on treating diabetes and its vision complications, a new study shows.
Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.
› Verified 3 days ago
| Entity Name | Optima Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831187764 PECOS PAC ID: 3971561648 Enrollment ID: O20220329002691 |
News Archive
A team of scientists from Spain has recently evaluated the immune responses induced by mRNA-based Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine in healthcare workers with or without a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Today, the Mental Health Now, or mhNOW, initiative will launch at the inaugural Financing and Innovation in Global Health (FIGH) conference. Led by mental health experts Chris Underhill, founder and president of BasicNeeds, and Moitreyee Sinha, head of health at the Global Development Incubator (GDI), mhNOW is a global, collective action including social entrepreneurs, organizations and companies that are working together to innovate and identify mental health solutions on a global scale, and systemically implement in communities at a local level.
A new vision screening device, already shown to give an early warning of eye disease, could give doctors and patients a head start on treating diabetes and its vision complications, a new study shows.
Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Molly Ce Cowdrey, MD 111 New Hampshire Ave Ste 2, Portsmouth, NH 03801-2864 Ph: (802) 909-2053 | Molly Ce Cowdrey, MD 176 S River Rd, Bedford, NH 03110-7061 Ph: (802) 909-2053 |
News Archive
A team of scientists from Spain has recently evaluated the immune responses induced by mRNA-based Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine in healthcare workers with or without a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Today, the Mental Health Now, or mhNOW, initiative will launch at the inaugural Financing and Innovation in Global Health (FIGH) conference. Led by mental health experts Chris Underhill, founder and president of BasicNeeds, and Moitreyee Sinha, head of health at the Global Development Incubator (GDI), mhNOW is a global, collective action including social entrepreneurs, organizations and companies that are working together to innovate and identify mental health solutions on a global scale, and systemically implement in communities at a local level.
A new vision screening device, already shown to give an early warning of eye disease, could give doctors and patients a head start on treating diabetes and its vision complications, a new study shows.
Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.
› Verified 3 days ago
Jennifer Ann Stead, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 176 S River Rd, Bedford, NH 03110 Phone: 603-942-2003 Fax: 603-403-7809 |